坎伯兰药业 CPIX 深 沪
等待开盘 10-09 09:30:00 美东时间
3.674
+0.114
+3.20%
华盛通- 最 高3.68
- 今 开3.56
- 成交量 4.52万股
- 最 低 3.40
- 昨 收 3.56
- 总市值 5496.27万
- 52周最高 7.25
- 市盈率 静 --
- 换手率 0.30%
- 52周最低 1.04
- 委 比 -89.22%
- 总股本 1495.99万
- 历史最高 8.02
- 量 比 1.46
- 振 幅 7.87%
- 历史最低 1.04
- 每 手 1
- 风险率 1.46%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多CUMBERLAND PHARMACEUTICALS ANNOUNCES PRODUCT APPROVAL IN MEXICO
Injectable Ibuprofen Approved for Treating Pain & Fever NASHVILLE, Tenn., Oct. 1 , 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, to...
10-01 21:05
TABUK LAUNCHES VIBATIV® FDA-APPROVED ANTIBIOTIC WITH LIFE-SAVING POTENTIAL IN SAUDI ARABIA
Vibativ ® treats patients with pneumonia and serious skin infections NASHVILLE, Tenn. and RIYADH, Saudi Arabia, Sept. 29, 2025 /PRNewswire/ -- Specialty pharmaceutical companies Tabuk Pharm...
09-29 21:05
Cardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology宣布其管理层将参加2025年9月的三场投资者会议，包括Wells Fargo、Morgan Stanley和H.C. Wainwright的年度医疗与投资大会。公司通过PLK1抑制剂开发抗癌疗法，重点治疗结直肠癌、胰腺癌等。会议详情见公司网站。
08-28 20:05
Cumberland Pharmaceuticals reports Q2 results
Cumberland Pharmaceuticals press release (NASDAQ:CPIX): Q2 GAAP EPS of -$0.05 Revenue of $10.8M (+9.1% Y/Y). More on Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. (CPIX) Q2 2025 Earnings ...
08-06 14:40
Cumberland Q2 Adj. EPS $0.18 Up From $0.01 YoY, Sales $10.800M Up From $9.849M YoY
Cumberland (NASDAQ:CPIX) reported quarterly earnings of $0.18 per share. This is a 1700 percent increase over earnings of $0.01 per share from the same period last year. The company reported $10.800 million in sales
08-06 04:13
Cumberland Pharmaceuticals Reports 23% Revenue Growth Year-to-Date
NASHVILLE, Tenn., Aug. 5, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved ...
08-06 04:05
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Cumberland Pharma Announces Availability Of Vibativ 4-Vial Starter Pak Through New Contract With Vizient
Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centersNASHVILLE, Tenn., Aug. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty
08-04 21:06
CUMBERLAND PHARMACEUTICALS RECEIVES VIZIENT CONTRACT FOR NEW VIBATIV® 4-VIAL STARTER PAK
Vizient serves more than 65% of the nation's acute care providers, including 97% of academic medical centers NASHVILLE, Tenn., Aug. 4, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (N...
08-04 21:05
Cumberland Pharma Presents Latest Results From Phase 2 FIGHT DMD Trial Evaluating Ifetroban, Oral Therapy For DMD Heart Disease, At PPMD Conference In Las Vegas
New pharmacokinetic and cardiac biomarker data further demonstrate ifetroban's potential to protect the heart and reduce cardiac damage in DMD patientsNASHVILLE, Tenn., June 23, 2025 /PRNewswire/ -- Cumberland
06-23 21:09
